GT Biopharma Inc (GTBP) - Total Liabilities
Based on the latest financial reports, GT Biopharma Inc (GTBP) has total liabilities worth $2.42 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GTBP asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
GT Biopharma Inc - Total Liabilities Trend (1983–2025)
This chart illustrates how GT Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see GT Biopharma Inc asset portfolio.
GT Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of GT Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Asuransi Dayin Mitra Tbk
JK:ASDM
|
Indonesia | Rp389.61 Billion |
|
Origin Agritech Ltd
NASDAQ:SEED
|
USA | $168.09 Million |
|
Standard Industries Limited
NSE:SIL
|
India | Rs441.07 Million |
|
Investsmart Group Ltd
AU:INV
|
Australia | AU$6.41 Million |
|
Saray Matbaacilik Kagitcilik Kirtasiyecilik Ticaret ve Sanayi AS
IS:SAMAT
|
Turkey | TL155.52 Million |
|
Adagio Medical Holdings, Inc Common Stock
NASDAQ:ADGM
|
USA | $34.30 Million |
|
PATERSON RESOURCES LTD
F:U40
|
Germany | €687.06K |
Liability Composition Analysis (1983–2025)
This chart breaks down GT Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of GT Biopharma Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GT Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GT Biopharma Inc (1983–2025)
The table below shows the annual total liabilities of GT Biopharma Inc from 1983 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.32 Million | -60.71% |
| 2024-12-31 | $5.90 Million | -11.02% |
| 2023-12-31 | $6.63 Million | +32.61% |
| 2022-12-31 | $5.00 Million | -51.24% |
| 2021-12-31 | $10.26 Million | -70.77% |
| 2020-12-31 | $35.09 Million | +78.09% |
| 2019-12-31 | $19.71 Million | +40.47% |
| 2018-12-31 | $14.03 Million | +423.67% |
| 2017-12-31 | $2.68 Million | -85.86% |
| 2016-12-31 | $18.95 Million | -62.57% |
| 2015-12-31 | $50.62 Million | +66.18% |
| 2014-12-31 | $30.46 Million | +370.02% |
| 2013-12-31 | $6.48 Million | -1.23% |
| 2012-12-31 | $6.56 Million | +25.47% |
| 2011-12-31 | $5.23 Million | -7.50% |
| 2010-12-31 | $5.65 Million | -20.46% |
| 2009-12-31 | $7.11 Million | +66.46% |
| 2008-12-31 | $4.27 Million | +32.28% |
| 2007-12-31 | $3.23 Million | -58.63% |
| 2006-12-31 | $7.80 Million | +82.80% |
| 2005-12-31 | $4.27 Million | +59.25% |
| 2004-12-31 | $2.68 Million | +145.20% |
| 2003-12-31 | $1.09 Million | +42.50% |
| 2002-12-31 | $767.00K | -35.44% |
| 2001-12-31 | $1.19 Million | -23.45% |
| 2000-12-31 | $1.55 Million | -37.80% |
| 1999-12-31 | $2.50 Million | -37.63% |
| 1998-12-31 | $4.00 Million | -31.03% |
| 1997-12-31 | $5.80 Million | +65.71% |
| 1996-12-31 | $3.50 Million | -37.50% |
| 1995-12-31 | $5.60 Million | +24.44% |
| 1994-12-31 | $4.50 Million | +1400.00% |
| 1993-12-31 | $300.00K | -50.00% |
| 1992-12-31 | $600.00K | +200.00% |
| 1991-12-31 | $200.00K | 0.00% |
| 1990-12-31 | $200.00K | -60.00% |
| 1989-12-31 | $500.00K | +66.67% |
| 1988-12-31 | $300.00K | +50.00% |
| 1987-12-31 | $200.00K | -60.00% |
| 1986-12-31 | $500.00K | +400.00% |
| 1985-12-31 | $100.00K | -66.67% |
| 1984-12-31 | $300.00K | -25.00% |
| 1983-12-31 | $400.00K | -- |
About GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, tha… Read more